Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I don't sell. I add more when it pulls back. I don't buy on margin. I don't set stop loss. What can the manipulators/shorts or their employees do to my AUPH shares and my money? Ah? AUPH has very bright future. Patience is the key. I believe AUPH will be my next ARIA. I buy and hold AUPH the way I bought and held ARIA. I'm planning to add more AUPH shares now that the Glickman-Cramer interview has offered a new opportunity. I always picked/pick up the gold bags of ARIA/AUPH shares whenever the price was/is right to me. I like cheapened gold bags.
Peter Lynch: "If you like a stock at $14 and it goes to $8, that's good if you understand the company. Take advantage of these declines. If you own good companies, you'll do well. It's always going to be scary, there's going to be always something to worry about, and you just have to forget about all of that. Know what you own and know why you own it." Isn't Aurinia a good company given it has many +'s & its revenue is conservatively estimated to be $4B by 2022? - https://en.wikipedia.org/wiki/Peter_Lynch
I read your posts as well. I like your intuitions on
picking a good investment (with a little help from vidpok,
at least for me), AND your dogged stubborness in sticking
with your convictions. It's not a guarantee that it will work
out, BUT is sure did with Ariad, and I believe it will also
have similar results here (minus the drama there).
I cannot think of another biotech where the probability
for a favorable outcome is as good as AUPH. The people
running the show are top notch, have deep experience in
both the specific science (LN related issues), and the
business acumen based on a very similar (almost
the same) medical and business situation.
While it might take two years for approval, I think we'll
see upward movement before that, after all, Aurinia does
have other indications for Voc. and potential for deal-making.
Good luck to you and fellow longs,
zzaatt/amp
PS: This two year (blinded) wait seems pretty grotesque, given the
strong results in P2 and the fact that it will cost the lives
of thousands of very desperate patients. I always had a
profound contempt for the corrupt, hide-bound bureaucracy
known as the FDA and I'm hoping for big changes under Dr.Gottlieb!
Who knows, maybe some conditional approval may be possible,
it certainly should be, if the goal is to help sick people.
Stellar management team, great science, Aspreva success, stellar VOC P2 results, expertise in trial design, FDA Fast Track status, etc. I simply believe that when you add it all up, it significantly boosts their odds of success in P3.
"Hard to find a better risk/reward play than AUPH."
LJIN KNOWS ABOUT AUPH and ALL THE Voc STORIES DEFINATELY BETTER THAN the munipulators/short hedge funds' employees. ILJIN has Dr. Hyuek Joon Lee on AUPH's board of directors. ILJIN has been being the absolutely #1 AUPH owner/investor since 2011. Why did ILJIN still acquire 20% or 5,185,185 shares of the 25,645,000 shares offered at $6.7 publicly on 03-13-2017? ILJIN knows AUPH shares are GOLD BAGS based on Voc 's phase 2 results updated in early 2017, doesn't it? ILJIN owns 17.35% of AUPH (14,205,457 shares) now.
Peter Lynch: "If you like a stock at $14 and it goes to $8, that's good if you understand the company. Take advantage of these declines. If you own good companies, you'll do well. It's always going to be scary, there's going to be always something to worry about, and you just have to forget about all of that. Know what you own and know why you own it." Isn't Aurinia a good company given it has many +'s & its revenue is conservatively estimated to be $4B by 2022? - https://en.wikipedia.org/wiki/Peter_Lynch
I don't set stop loss. I don't buy on margin. I don't sell. I add more when it pulls back. What can the manipulators/shorts or their employees such as ... do to my AUPH shares and my money? Ah? AUPH has very bright future. Patience is the key. I believe AUPH will be my next ARIA. I buy and hold AUPH the way I bought and held ARIA. I'm planning to add more AUPH shares now that the Glickman-Cramer interview has offered a new opportunity. I always picked/pick up the gold bags of ARIA/AUPH shares whenever the price was/is right to me. I like cheapened gold bags.
I read your posts as well. I like your intuitions on
picking a good investment (with a little help from vidpok,
at least for me), AND your dogged stubborness in sticking
with your convictions. It's not a guarantee that it will work
out, BUT is sure did with Ariad, and I believe it will also
have similar results here (minus the drama there).
I cannot think of another biotech where the probability
for a favorable outcome is as good as AUPH. The people
running the show are top notch, have deep experience in
both the specific science (LN related issues), and the
business acumen based on a very similar (almost
the same) medical and business situation.
While it might take two years for approval, I think we'll
see upward movement before that, after all, Aurinia does
have other indications for Voc. and potential for deal-making.
Good luck to you and fellow longs,
zzaatt/amp
PS: This two year (blinded) wait seems pretty grotesque, given the
strong results in P2 and the fact that it will cost the lives
of thousands of very desperate patients. I always had a
profound contempt for the corrupt, hide-bound bureaucracy
known as the FDA and I'm hoping for big changes under Dr.Gottlieb!
Who knows, maybe some conditional approval may be possible,
it certainly should be, if the goal is to help sick people.
I like old reports - Leerink: "75% probability of success. We rate AUPH Outperform. AUPH is run by a management team with deep experience in lupus nephritis (LN) and corporate development, having executed the ALMS study for CellCept and selling Aspreva and ZymoGenetics to large pharma companies. We project a ~$1.35BN gross market opportunity for voclosporin in the US and a 75% probability of success. Promising Phase 2b results presented in 2016 and updated in early 2017 continue to derisk Voclosporin development."
https://www.docdroid.net/CIKaxJ9/aurinia-pharmaceuticals-inc-leerink1.pdf
The older the report, the better. This report is only about 5 months old, I know.
I added 2,000 shares yesterday at 5.84/5.77. Unfortunately my 4 limit orders (1,000 shares limited at 5.66, 1,000 shares at 5.55, 1,000 shares at 5.44 & 1,000 shares at 5.33) were not filled. The shorts/manapulators and their employees such as BR, Jonathon and humour412 should have worked harder to bring this stock much lower to help have all my limit orders filled. I don't set stop loss. I don't buy on margin. I don't sell. I add more when it pulls back. What can the manipulators and their employees like BR/iandy/dave/MO/Bruce/humour412 do to my AUPH shares and my money? Ah? AUPH has very bright future. Patience is the key. I believe AUPH will be my next ARIA. I always picked/pick up the gold bags of ARIA/AUPH shares whenever the price was/is right to me. I buy and hold AUPH the way I bought and held ARIA. I like cheapened gold bags.
Lynch:"If you like a stock at $14 and it goes to $8, that's good if you understand the company. Take advantage of these declines. If you own good companies, you'll do well. It's always going to be scary, there's going to be always something to worry about, and you just have to forget about all of that. Know what you own and know why you own it." - https://en.wikipedia.org/wiki/Peter_Lynch - Isn't Aurinia a good company given it has many +'s & its revenue is conservatively estimated to be $4B by 2022?
I don't set stop loss. I don't buy on margin. I don't sell. I add more when it pulls back. What can the manipulators/shorts or their employees such as BR/dave/MO/Bruce/humour412 do to my AUPH shares and my money? Ah? AUPH has very bright future. Patience is the key. I believe AUPH will be my next ARIA. I buy and hold AUPH the way I bought and held ARIA. I'm planning to add more AUPH shares now that the Glickman-Cramer interview has offered a new opportunity. I always picked/pick up the gold bags of ARIA/AUPH shares whenever the price was/is right to me. I like cheapened gold bags. - This is posted by ariadinvestor: https://finance.yahoo.com/quote/AUPH/community?p=AUPH
Not so, I read your posts as well. I like your intuitions on
picking a good investment (with a little help from vidpok,
at least for me), AND your dogged stubborness in sticking
with your convictions. It's not a guarantee that it will work
out, BUT is sure did with Ariad, and I believe it will also
have similar results here (minus the drama there).
I cannot think of another biotech where the probability
for a favorable outcome is as good as AUPH. The people
running the show are top notch, have deep experience in
both the specific science (LN related issues), and the
business acumen based on a very similar (almost
the same) medical and business situation.
While it might take two years for approval, I think we'll
see upward movement before that, after all, Aurinia does
have other indications for Voc. and potential for deal-making.
Good luck to you and fellow longs,
zzaatt/amp
PS: This two year (blinded) wait seems pretty grotesque, given the
strong results in P2 and the fact that it will cost the lives
of thousands of very desperate patients. I always had a
profound contempt for the corrupt, hide-bound bureaucracy
known as the FDA and I'm hoping for big changes under Dr.Gottlieb!
Who knows, maybe some conditional approval may be possible,
it certainly should be, if the goal is to help sick people. - https://investorshub.advfn.com/boards/read_msg.aspx?message_id=133437830
I don't set stop loss. I don't buy on margin. I don't sell. I add more when it pulls back. What can the manipulators/shorts or their employees such as BR/dave/MO/Bruce/humour412 do to my AUPH shares and my money? Ah? AUPH has very bright future. Patience is the key. I believe AUPH will be my next ARIA. I buy and hold AUPH the way I bought and held ARIA. I'm planning to add more AUPH shares now that the Glickman-Cramer interview has offered a new opportunity. I always picked/pick up the gold bags of ARIA/AUPH shares whenever the price was/is right to me. I like cheapened gold bags.
Peter Lynch: "If you like a stock at $14 and it goes to $8, that's good if you understand the company. Take advantage of these declines. If you own good companies, you'll do well. It's always going to be scary, there's going to be always something to worry about, and you just have to forget about all of that. Know what you own and know why you own it." Isn't Aurinia a good company given it has many +'s & its revenue is conservatively estimated to be $4B by 2022? - https://en.wikipedia.org/wiki/Peter_Lynch
- This is posted by ariadinvestor: https://finance.yahoo.com/quote/AUPH/community?p=AUPH
zzaatt replied to me:
Not so, I read your posts as well. I like your intuitions on
picking a good investment (with a little help from vidpok,
at least for me), AND your dogged stubborness in sticking
with your convictions. It's not a guarantee that it will work
out, BUT is sure did with Ariad, and I believe it will also
have similar results here (minus the drama there).
I cannot think of another biotech where the probability
for a favorable outcome is as good as AUPH. The people
running the show are top notch, have deep experience in
both the specific science (LN related issues), and the
business acumen based on a very similar (almost
the same) medical and business situation.
While it might take two years for approval, I think we'll
see upward movement before that, after all, Aurinia does
have other indications for Voc. and potential for deal-making.
Good luck to you and fellow longs,
zzaatt/amp
PS: This two year (blinded) wait seems pretty grotesque, given the
strong results in P2 and the fact that it will cost the lives
of thousands of very desperate patients. I always had a
profound contempt for the corrupt, hide-bound bureaucracy
known as the FDA and I'm hoping for big changes under Dr.Gottlieb!
Who knows, maybe some conditional approval may be possible,
it certainly should be, if the goal is to help sick people.
I like your intuitions on
picking a good investment, AND your dogged stubborness in sticking
with your convictions. It's not a guarantee that it will work
out, BUT is sure did with Ariad, and I believe it will also
have similar results here (minus the drama there).
I cannot think of another biotech where the probability
for a favorable outcome is as good as AUPH. The people
running the show are top notch, have deep experience in
both the specific science (LN related issues), and the
business acumen based on a very similar (almost
the same) medical and business situation.
While it might take two years for approval, I think we'll
see upward movement before that, after all, Aurinia does
have other indications for Voc. and potential for deal-making.
Good luck to you and fellow longs,
zzaatt/amp
PS: This two year (blinded) wait seems pretty grotesque, given the
strong results in P2 and the fact that it will cost the lives
of thousands of very desperate patients. I always had a
profound contempt for the corrupt, hide-bound bureaucracy
known as the FDA and I'm hoping for big changes under Dr.Gottlieb!
Who knows, maybe some conditional approval may be possible,
it certainly should be, if the goal is to help sick people.
".... hoping for big changes under Dr.Gottlieb!
Who knows, maybe some conditional approval may be possible, ...."
Good point- what are they waiting for? Why not approve treatment today and do a Phase 4 instead? VOC has been thoroughly tested by more than 2000 people and shown to be very safe, it's shown to be effective as well so the downside is either very small or non-existent.
Seems stupid when the upside of helping suffering people (saving lives) is considered. Hate the bureaucratic overkill rules and regs of gov't.
No wonder the average cost of bringing a new drug to market in the USA is something like 2.6 billion and takes years and years.
There has to be a better way.
ILJIN KNOWS ABOUT ALL THE Voclosporin STORIES DEFINATELY BETTER THAN BR, humour412, socialidiocies and Flyingtrader. ILJIN has Dr. Hyuek Joon Lee on AUPH's board of directors. ILJIN has been being the absolutely #1 AUPH owner/investor since 2011. Why did ILJIN still acquire 20% or 5,185,185 shares of the 25,645,000 shares offered publicly on 03-13-2017? ILJIN knows AUPH shares are GOLD BAGS based on the phase 2 results updated in early 2017, doesn't it? ILJIN owns 17.35% of AUPH (14,205,457 shares) now. I don't think the faithful true longs' confidence on AUPH would be shaken by BR and humour412.
Quote: "ILJIN Life Science Co., Ltd. engages in the clinical and commercial development of voclosporin. The company is based in South Korea. ILJIN Life Science Co., Ltd. operates as a subsidiary of Iljin Holdings Co., Ltd. - https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=126747582
Dr. Hyuek Joon Lee is the Director of New Business Development for ILJIN Group and is responsible for mergers and acquisitions, and managing overseas investments, joint ventures and subsidiaries. As of October 2014 he joined the board of directors of Life Science Enterprises in Massachusetts, ..." Link: http://insiders.morningstar.com/trading/executive-profile.action?t=0P0000BLCT&PersonId=PS0000A8VP&flag=Director&insider=Hyuek_Lee&culture=en-CA&productcode=CAN&ops=clear&cur=
https://relationshipscience.com/hyuek-joon-lee-p157816980
This is Posted by ariadinvestor:
https://finance.yahoo.com/quote/AUPH/community?p=AUPH
"ILJIN's Hyuek Joon Lee is on AUPH's board of directors. ILJIN knows about any of the Voclosporin stories definitely better than BR, humour412, socialidiocies and Flyingtrader. ILJIN has been being the absolutely #1 AUPH owner/investor since 2011. Why did ILJIN still acquire 20+% or 5,185,185 shares of the 25,645,000 shares offered publicly on 03-13-2017? AUPH is good, isn't it? LJIN owns 17.35% of AUPH (14,205,457 shares) now after it added 5,185,185 shares at $6.75 in March. I don't think Katrina's confidence on AUPH would be shaken by BR and humour412."
https://relationshipscience.com/hyuek-joon-lee-p157816980
Dr. Hyuek Joon Lee is the Director of New Business Development for ILJIN Group and is responsible for mergers and acquisitions, and managing overseas investments, joint ventures and subsidiaries. As of October 2014 he joined the board of directors of Life Science Enterprises in Massachusetts, ..." Link: http://insiders.morningstar.com/trading/executive-profile.action?t=0P0000BLCT&PersonId=PS0000A8VP&flag=Director&insider=Hyuek_Lee&culture=en-CA&productcode=CAN&ops=clear&cur=
This is Posted by ariadinvestor:
https://finance.yahoo.com/quote/AUPH/community?p=AUPH
Leerink: "Outperform. Success probability=75%. AUPH is run by a management team with deep experience in lupus nephritis (LN) and corporate development, having executed the ALMS study for CellCept and selling Aspreva and ZymoGenetics to large pharma companies. We project a ~$1.35BN gross market opportunity for voclosporin in the US and a 75% probability of success. Promising Phase 2b results presented in 2016 and updated in early 2017 continue to derisk Voclosporin development."
https://www.docdroid.net/CIKaxJ9/aurinia-pharmaceuticals-inc-leerink1.pdf
I like the report because it is about 5 months old.
Leerink:"Voclosporin derisked. 75% probability of success. We rate AUPH Outperform. AUPH is run by a management team with deep experience in lupus nephritis (LN) and corporate development, having executed the ALMS study for CellCept and selling Aspreva and ZymoGenetics to large pharma companies. We project a ~$1.35BN gross market opportunity for voclosporin in the US and a 75% probability of success. Promising Phase 2b results presented in 2016 and updated in early 2017 continue to derisk Voclosporin development."
https://www.docdroid.net/CIKaxJ9/aurinia-pharmaceuticals-inc-leerink1.pdf
Please feel free to tell me this report about 5 months old. Nobody reads my posts anyway.
Leerink: "75% probability of success. We rate AUPH Outperform. AUPH is run by a management team with deep experience in lupus nephritis (LN) and corporate development, having executed the ALMS study for CellCept and selling Aspreva and ZymoGenetics to large pharma companies. We project a ~$1.35BN gross market opportunity for voclosporin in the US and a 75% probability of success. Promising Phase 2b results presented in 2016 and updated in early 2017 continue to derisk Voclosporin development."
https://www.docdroid.net/CIKaxJ9/aurinia-pharmaceuticals-inc-leerink1.pdf
zzaattt only:"AUPH is run by a management team with deep experience in lupus nephritis (LN) and corporate development, having executed the ALMS study for CellCept and selling Aspreva and ZymoGenetics to large pharma companies ... " - https://www.docdroid.net/CIKaxJ9/aurinia-pharmaceuticals-inc-leerink1.pdf
Hotrodder/Foxxy says nobody my posts about AUPH. LOL!
Hotrodder/Foxxy, nobody but you read my posts about AUPH. Thank you very much.
"I don't set stop loss. I don't buy on margin. I don't sell. I add more when it pulls back. What can the manipulators/shorts do to my AUPH shares and my money? Ah? AUPH has very bright future. Patience is the key. I believe AUPH will be my next ARIA. I buy and hold AUPH the way I bought and held ARIA. I'm planning to add more AUPH shares now that the Glickman-Cramer interview has offered a new opportunity. I always picked/pick up the gold bags of ARIA/AUPH shares whenever the price was/is right to me. I like cheapened gold bags."
- Posted by ariadinvestor:
https://finance.yahoo.com/quote/AUPH/community?p=AUPH
Lunacy, another hubby I'm thinking about, but it must be as entertaining as my current one. Thank you very much for your advice. You know about AUPH than anybody else on any AUPH discussion forums. Thank you!
ILJIN has been being the absolutely #1 AUPH owner/investor since 2011. With the recently acquired 5,185,185 shares at $6.75 from the latest public offering, ILJIN owns 17.35% of AUPH (14,205,457 shares). Doesn't ILJIN love AUPH/Voclosporin? ILJIN definitely knows about Voclosporin better than any of us here. QUOTE: "ILJIN Life Science Co., Ltd. engages in the clinical and commercial development of Voclosporin. The company is based in South Korea. ILJIN Life Science Co., Ltd. operates as a subsidiary of Iljin Holdings Co., Ltd." - https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=126747582
This is posted by ariadinvestor:
https://finance.yahoo.com/quote/AUPH/community?p=AUPH
@?: YorkBug said I brought nothing here. He ordered me to go away. He said he kept blocking me but always failed. It true that I've brought nothing to this board. But I am not in jailhouse. Hypocrite YorkBug has contributed a great deal to this board. But he is in jailhouse now. LOL! Fortunately, TC serves him well in the jailhouse. YorkBug, TC and I are on the same side. We are all faithful AUPH longs. Why am I posting this? YorkBug and TC know it.
Vid, thank you for letting us know AUPH. YorkBug hates Berger because Hypocrite YorkBug added 10,000 ARIA shares at $20 right before the 2013-10-09 flash crash. YorkBug who confessed he's a hypocrite in jailhouse thinks he was misled by Berger. Berger/Glickman was/is honest about ARIA/AUPH.
I strike back the provocations of anyone even if the provoking is my friend.
Vid, thank you for letting us know AUPH. YorkBug hates Berger because Hypocrite YorkBug added 10,000 ARIA shares at $20 right before the 2013-10-09 flash crash. YorkBug who confessed he's a hypocrite in jailhouse thinks he was misled by Berger. Berger/Glickman was/is honest about ARIA/AUPH.
I have brought nothing to this board. But I am not in jailhouse. Hypocrite YorkBug has contributed a great deal to this board. But he is in jailhouse now. Fortunately, TC serves him well in the house. YorkBug, TC and I are on the same side. We are all faithful AUPH longs. Why am I posting this? YorkBug and TC know it.
I like Glickman's honesty. All small biotech stocks are speculative, aren't they? Why not Aurinia? ARIA was also a speculative stock. The ARIA believers such as Jesspro, zzaatt, vidpok45 and me speculated ARIA. We made millions from our speculations.
-- Posted by ariadinvestor:
https://finance.yahoo.com/quote/AUPH/community?p=AUPH
Patience and persistence worked out for us at Ariad,
I think this investment is past the "speculative" phase
and into the almost!!! certain territory.
Best to you and other Ariad alumni,
zzaatt/amp
Glickman/Berger is extremely bright and honest.
Actually they have a lot in common: extremely bright, driven, energetic entrepreneurial guys who change the world for the better!
"Glickman hit all the highlights in that too brief segment: 5X the efficacy of current SOC, only 1 P3 required, $200M in cash with no further funding needed, more VOC indications coming in the fall, etc. Cramer came across as Cramer; Glickman came across as a man of integrity on a mission (this is a speculative stock)." - Yes, all small biotech stocks are speculative, aren't they? Why not Aurinia? I like Glickman's honesty. ARIA was also a speculative stock. The ARIA believers such as Jesspro, zzaatt, ariadinvestor, vidpok45 and me speculated ARIA. We made millions from our speculations.
Berger/Glickman was/is honest about AUPH/ARIA. YorkBug hates Berger because Hypocrite YorkBug added 10,000 ARIA shares at $20 right before the 2013-10-09 flash crash. YorkBug who confessed he's a hypocrite in jailhose thinks he was misled by Berger. Where is Harvey Berger now?
Medinol Announces Appointment Of Harvey J. Berger, M.D., As Executive Chairman Of Medinol US.
http://www.prnewswire.com/news-releases/medinol-announces-appointment-of-harvey-j-berger-md-as-executive-chairman-of-medinol-us-300408859.html
Whenever Ariad CEO Harvey Berger was interviewed by Cramer, the share price dropped right away, which offered opportunities to the ARIA believers such as Jesspro, zzaatt, ariadinvestor, vidpok45 and me to buy/add shares at cheapened prices. I would probably add more AUPH shares should the Glickman-Cramer interview offer a new opportunity, depending how much it would cheapen the share price. Cheers, AUPH longs
Berger/Glickman was/is honest about ARIA/AUPH. YorkBug hates Berger because Hypocrite YorkBug added 10,000 ARIA shares at $20 right before the 2013-10-09 flash crash. YorkBug who confessed he's a hypocrite in jailhouse thinks he was misled by Berger. Where is Harvey Berger now?
Medinol Announces Appointment Of Harvey J. Berger, M.D., As Executive Chairman Of Medinol US.
http://www.prnewswire.com/news-releases/medinol-announces-appointment-of-harvey-j-berger-md-as-executive-chairman-of-medinol-us-300408859.html
Whenever Ariad CEO Harvey Berger was interviewed by Cramer, the share price dropped right away, which offered opportunities to the ARIA believers such as Jesspro, zzaatt, ariadinvestor, vidpok45 and me to buy/add shares at cheapened prices. I would probably add more AUPH shares should the Glickman-Cramer interview offer a new opportunity, depending how much it would cheapen the share price. Cheers, AUPH longs
Vidpok: "Duggan would be to Aurinia what Denner was to Ariad. Max value if he gets on the board."
Araidinvestor posted 2 months ago: ""Will Robert Duggan to Aurinia be Alex Denner to Ariad? I hope so. Robert Duggan Takes a 7.2% Stake in Aurinia (5,766,887 shares @6.50-8.85, AVG price 7.50?). This is great AUPH news to me."
https://finance.yahoo.com/quote/AUPH/community?p=AUPH
Glickman/Berger is/was honest about AUPH/ARIA. Vidpok45 hates Berger because Vid added 10,000 ARIA shares at $20 before the 2013-10-09 flash crash. Vid thinks he was misled by Berger. Where is Harvey Berger now?
Medinol Announces Appointment Of Harvey J. Berger, M.D., As Executive Chairman Of Medinol US.
http://www.prnewswire.com/news-releases/medinol-announces-appointment-of-harvey-j-berger-md-as-executive-chairman-of-medinol-us-300408859.html
"Whenever Ariad CEO Harvey Berger was interviewed by Cramer, the share price dropped right away, which offered opportunities to the ARIA believers such as Jesspro, zzaatt, ariadinvestor, vidpok45 and me to buy/add shares at cheapened prices. I would probably add more AUPH shares should the Glickman-Cramer interview offer a new opportunity, depending how much it would cheapen the share price. Cheers, AUPH longs!"
- Posted by ariadinvestor
https://finance.yahoo.com/quote/AUPH/community?p=AUPH
Shorts, please don't cover at 6.75. You will have tons of chances to cover at 7.75, 8.75, 9.75, ..., 16.75, 26.75, 36.75 and ... Why cover now? Aren't 7.75, 8.75, 9.75, ..., 16.75, 26.75, 36.75 and ... higher than 6.75? The math is so simple. Just take it easy. Why cover at 6.75now?
- Posted by ariadinvestor
https://finance.yahoo.com/quote/AUPH/community?p=AUPH
Hot, shorting hard I've been since I liquidated at $5.99 all my 3 shares in 6 accounts. I told you I'd liquidated all my shares in all accounts and short hard if it fell below 6. I can afford to short as many as 2 shares since I have made a fortune from joining a class action lawsuit against Ariad. I received $0.001 per 1,000 ARIA shares I sold at $2.xx, which is more than enough to cover the cost for borrowing 2 shares to short. I was/am honest about my ARIA/AUPH positions. You would be a fool if you didn't believe me.
Why double-blinded? Cuz phase 2 shows particular promise (amazingly good data). A double-blinded study is used after initial studies show particular promise, which is defined by MedicineNet.com
http://www.medicinenet.com/script/main/art.asp?articlekey=11177
Voclosporin's phase 2 trial has shown particular promise (amazingly good results). That's why its phase 3 trial is double-blinded. Aurinia has very bright future. Patience is the key to the big success of an AUPH true long's investment. A few true longs such as Jesspro, vidpok45, zzaatt, ariadinvestor and TC might own more ARIA shares than me. We had patience and we made millions on ARIA. We will make more on AUPH.
Quote: "Nothing but the clinical trial data are the determinants. I infer about the success of Voclosporin's phase 3 not that it is double-blinded but that its design is almost identical to phase 2, which has delivered amazingly good data. And it is believed that Phase 3 results will be even stronger than Phase 2 because better selection of clinical trial sites & healthier patients. A double-blinded study is used after initial studies show particular promise. Voclosporin's phase 2 study has shown particular promise (amazingly good results). That's why its phase 3 study is double-blinded."
https://finance.yahoo.com/quote/AUPH/community?p=AUPH
AUPH CEO Glickman says $4 billion market by 2022 ( http://bloombergtv.ca/2017-05-18/news/phase-iii-trials-underway-for-aurinia-pharmaceuticals-lupus-drug/ ). Motley Fool: "Sky's the limit - Peak U.S. Market Value = $6 billion assuming the low end of both patient population and pricing. EU patient population = 175,000 - 250,000. Aurinia looks to be significantly undervalued." - https://www.fool.com/investing/2017/03/31/aurinia-pharmaceuticals-where-to-from-here.aspx
This was posted by AI:
https://finance.yahoo.com/quote/AUPH/community?p=AUPH
Hot, I've been shoring hard since I liquidated at $5.99 all my 3 shares in 6 accounts. I told you I'd liquidated all my shares in all accounts and short hard if it fell below 6. I can afford to short as many as 2 shares since I have made a fortune from joining a class action lawsuit against Ariad. I received $0.001 per 1,000 ARIA shares I sold at $2.xx, which is more than enough to cover the cost for borrowing 2 shares to short. I was/am honest about my ARIA/AUPH positions. You would be a fool if you didn't believe me.
I've been shoring hard since I liquidated at $5.99 all my 3 shares in 6 accounts. I told you I'd liquidated all my shares in all accounts and short hard if it fell below 6. I can afford to short as many as 2 shares since I have made a fortune from joining a class action lawsuit against Ariad. I received $0.001 per 1,000 ARIA shares I sold at $2.xx, which is more than enough to cover the cost for borrowing 2 shares to short. I was/am honest about my ARIA/AUPH positions. You would be a fool if you didn't believe me.
I will claiming selling my ZERO AUPH shares at $79.75-$79.86 after the AUPH-buyout-at-$80 news is announced. I had been saying ARIA would drop to $2 and then it would bankrupt before I claimed I sold at $23.75-$23.86 on the ARIA-buyout-at-$24 news.
Why double-blinded? Cuz phase 2 shows particular promise (amazingly good data). A double-blinded study is used after initial studies show particular promise, which is defined by MedicineNet.com
http://www.medicinenet.com/script/main/art.asp?articlekey=11177
Voclosporin's phase 2 trial has shown particular promise (amazingly good results). That's why its phase 3 trial is double-blinded. Aurinia has very bright future. Patience is the key to the big success of an AUPH true long's investment. A few true longs such as Jesspro, vidpok45, zzaatt, ariadinvestor and TC might own more ARIA shares than me. We had patience and we made millions on ARIA. We will make more on AUPH.
Quote: "Nothing but the clinical trial data are the determinants. I infer about the success of Voclosporin's phase 3 not that it is double-blinded but that its design is almost identical to phase 2, which has delivered amazingly good data. And it is believed that Phase 3 results will be even stronger than Phase 2 because better selection of clinical trial sites & healthier patients. A double-blinded study is used after initial studies show particular promise. Voclosporin's phase 2 study has shown particular promise (amazingly good results). That's why its phase 3 study is double-blinded."
https://finance.yahoo.com/quote/AUPH/community?p=AUPH
Adam F:"Relax, you own a good company When $AUPH day traders become $AUPH shareholders…" -
When $AUPH day traders become $AUPH shareholders…
— Adam Feuerstein ✡️ (@adamfeuerstein) March 13, 2017
Relax, you own a good company. pic.twitter.com/kEdb9KpG9T
Twitter's alive with reasons why AUPH will drop to $2 like ARIA and then bankrupt even if P3 is halted and the LN drug is approved earlier by the FDA. I will claim selling my ZERO AUPH shares at $79.75-$79.86 after the AUPH-buyout-at-$80 news is announced. I had been saying ARIA would drop to $2 and then it would bankrupt before I claimed I sold at $23.75-$23.86 on the ARIA-buyout-at-$24 news
How to make AUPH drop to $2 and bankrupt it Glickman is thinking about. Like ARIA, AUPH will drop to $2 and then bankrupt even if P3 is halted and the LN drug is approved earlier by the FDA, which is why I bought ZERO shares in 100 accounts.
If it falls below $6, I will liquidate all my ZERO shares in 100 accounts and short hard again. I liquidated at $5.99 all my previous 3 shares in 6 accounts and shorted hard. I can afford to short as many as 2 shares since I have made a fortune from joining a class action lawsuit against Ariad. I received $0.001 per 1,000 ARIA shares I sold at $2.xx, which is more than enough to cover the cost for borrowing 2 shares to short. I was/am honest about my ARIA/AUPH positions. You would be a fool if you didn't believe me.